BMO Capital analyst Sean Dodge raised the firm’s price target on Medline (MDLN) to $54 from $45 and keeps an Outperform rating on the shares. The company’s Q4 results topped consensus even adjusting for a favorable tariff timing shift as demand remained strong across the business, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDLN: